See more : JFE Systems, Inc. (4832.T) Income Statement Analysis – Financial Results
Complete financial analysis of Galera Therapeutics, Inc. (GRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Galera Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Synovus Financial Corp. (SNV-PD) Income Statement Analysis – Financial Results
- Centrais Elétricas de Santa Catarina S.A. (CLSC4.SA) Income Statement Analysis – Financial Results
- Golden Goliath Resources Ltd. (GNG.V) Income Statement Analysis – Financial Results
- KOSAIDO Holdings Co., Ltd. (7868.T) Income Statement Analysis – Financial Results
- Mustang Energy PLC (MUST.L) Income Statement Analysis – Financial Results
Galera Therapeutics, Inc. (GRTX)
About Galera Therapeutics, Inc.
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 259.00K | 114.00K | 778.00K | 368.00K | 267.00K | 127.00K | 84.00K |
| Gross Profit | -259.00K | -114.00K | -778.00K | -368.00K | -267.00K | -127.00K | -84.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 24.12M | 31.01M | 52.42M | 54.85M | 42.33M | 18.66M | 20.59M |
| General & Administrative | 22.84M | 20.21M | 20.95M | 15.71M | 8.36M | 5.59M | 3.50M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.84M | 20.21M | 20.95M | 15.71M | 8.36M | 5.59M | 3.50M |
| Other Expenses | 0.00 | -11.07M | -7.17M | -3.68M | -1.25M | 0.00 | 0.00 |
| Operating Expenses | 46.95M | 51.23M | 73.37M | 70.55M | 50.69M | 24.26M | 24.09M |
| Cost & Expenses | 46.95M | 51.23M | 73.37M | 70.55M | 50.69M | 24.26M | 24.09M |
| Interest Income | 9.82M | 506.00K | 32.00K | 1.17M | 1.82M | 606.00K | 193.00K |
| Interest Expense | 0.00 | 11.57M | 7.19M | 4.88M | 3.03M | 220.00K | 0.00 |
| Depreciation & Amortization | 259.00K | 114.00K | 778.00K | 368.00K | 267.00K | 127.00K | 84.00K |
| EBITDA | -46.69M | -50.61M | -72.56M | -69.01M | -50.69M | -23.52M | -23.82M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -46.95M | -51.23M | -73.37M | -70.55M | -50.69M | -24.26M | -24.09M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -12.13M | -11.07M | -7.17M | -3.68M | -1.25M | 356.00K | 189.00K |
| Income Before Tax | -59.08M | -62.29M | -80.53M | -74.23M | -51.94M | -23.90M | -23.91M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -70.00K | 7.19M | -16.00K | -9.00K | -223.00K | -360.00K |
| Net Income | -59.08M | -62.22M | -87.73M | -74.22M | -51.93M | -23.68M | -23.55M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.33 | -2.30 | -3.40 | -2.98 | -2.09 | -1.22 | -1.55 |
| EPS Diluted | -1.33 | -2.30 | -3.40 | -2.98 | -2.09 | -1.22 | -1.55 |
| Weighted Avg Shares Out | 44.55M | 27.09M | 25.79M | 24.87M | 24.81M | 19.36M | 15.22M |
| Weighted Avg Shares Out (Dil) | 44.55M | 27.09M | 25.79M | 24.87M | 24.81M | 19.36M | 15.22M |
Galera to Present at Three Upcoming Investor Conferences in September
Galera Announces Completion of Enrollment in Pivotal 455-Patient Phase 3 Trial of Avasopasem for Severe Oral Mucositis
Galera Announces First Patient Dosed with GC4711 in Phase 2b GRECO-2 Trial in Patients with Pancreatic Cancer
Galera to Participate in the BofA Securities 2021 Virtual Healthcare Conference
GRTX Stock: From $6.61 To Over $8.80 Pre-Market Explanation
Galera Announces Updated Data from its Randomized, Multicenter, Placebo-Controlled Trial in Patients with Pancreatic Cancer
Galera Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference
Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
Galera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates
Galera Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports